GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)

ADA 2026 Scientific Sessions: New GLP-1 Drugs and Diabetes Research Highlights

In this JAMA Medical News podcast, Jennifer Abbasi interviews Dr. Rita Kalyani, the ADA's Chief Scientific and Medical Officer, about key hi

Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

ADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlighted

An interview with Dr. Rita Kalyani, the ADA's chief scientific and medical officer, discussing key research presented at the ADA 2026 Scient

Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials

GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

GLP-1 Receptor Agonists Linked to Small Risk of Smell and Taste Disturbances in Type 2 Diabetes

A study published in JAMA Otolaryngology-Head & Neck Surgery found that GLP-1 receptor agonists (RAs) used for type 2 diabetes are associate